Jinling Pharmaceutical Co Ltd Capital Reinvestment Ratio
Jinling Pharmaceutical Co Ltd capital reinvestment ratio. Jinling Pharmaceutical Co Ltd (000919) has a Capital Reinvestment Ratio of 0.17x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥74.01 Million) in capital expenditures (CN¥12.56 Million). Check Jinling Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Jinling Pharmaceutical Co Ltd (1999–2024)
Capital reinvestment ratio of Jinling Pharmaceutical Co Ltd from 1999 to 2024. This chart tracks Jinling Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. Also explore 000919 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Jinling Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1999–2024)
Jinling Pharmaceutical Co Ltd capital reinvestment ratio by year from 1999 to 2024. For the full cash flow conversion analysis, see cash flow conversion of Jinling Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.31x | CN¥154.19 Million | CN¥201.63 Million | ▲ +11.6% |
| 2023 | 1.17x | CN¥158.92 Million | CN¥186.25 Million | ▼ -1.4% |
| 2022 | 1.19x | CN¥260.59 Million | CN¥309.64 Million | ▲ +113.2% |
| 2021 | 0.56x | CN¥292.03 Million | CN¥162.76 Million | ▼ -40.4% |
| 2020 | 0.94x | CN¥311.46 Million | CN¥291.41 Million | ▲ +246.7% |
| 2019 | 0.27x | CN¥465.85 Million | CN¥125.71 Million | ▼ -14.2% |
| 2018 | 0.31x | CN¥433.83 Million | CN¥136.42 Million | ▲ +108.6% |
| 2017 | 0.15x | CN¥443.11 Million | CN¥66.80 Million | ▼ -86.5% |
| 2016 | 1.12x | CN¥96.15 Million | CN¥107.45 Million | ▲ +127.6% |
| 2015 | 0.49x | CN¥212.45 Million | CN¥104.31 Million | ▲ +61.6% |
| 2014 | 0.30x | CN¥299.89 Million | CN¥91.14 Million | ▼ -42.8% |
| 2013 | 0.53x | CN¥271.21 Million | CN¥144.05 Million | ▼ -34.7% |
| 2012 | 0.81x | CN¥232.12 Million | CN¥188.76 Million | ▲ +71.0% |
| 2011 | 0.48x | CN¥172.82 Million | CN¥82.20 Million | ▼ -11.4% |
| 2010 | 0.54x | CN¥177.81 Million | CN¥95.48 Million | ▲ +4.7% |
| 2009 | 0.51x | CN¥188.41 Million | CN¥96.60 Million | ▲ +607.8% |
| 2008 | 0.07x | CN¥305.26 Million | CN¥22.11 Million | ▼ -59.2% |
| 2007 | 0.18x | CN¥118.06 Million | CN¥20.97 Million | ▲ +6.5% |
| 2006 | 0.17x | CN¥138.50 Million | CN¥23.09 Million | ▼ -50.2% |
| 2005 | 0.33x | CN¥109.29 Million | CN¥36.61 Million | ▼ -26.1% |
| 2004 | 0.45x | CN¥159.81 Million | CN¥72.47 Million | ▲ +29.4% |
| 2003 | 0.35x | CN¥161.86 Million | CN¥56.73 Million | ▼ -55.5% |
| 2002 | 0.79x | CN¥130.36 Million | CN¥102.63 Million | ▼ -54.6% |
| 2001 | 1.73x | CN¥92.49 Million | CN¥160.27 Million | ▲ +198.0% |
| 2000 | 0.58x | CN¥231.31 Million | CN¥134.49 Million | ▼ -67.7% |
| 1999 | 1.80x | CN¥39.77 Million | CN¥71.57 Million | — |